1. A method of treating cancer selected from the group consisting of neuroblastoma, Ewings sarcoma or rhabdomyosarcoma comprising administering a therapeutically effective amount of a compound of formula (I) gdeA is heteroaryl selected from the group consisting of: R is one of the following substituents: (1) unsubstituted or substituted, preferably substituted C-alkyl, wherein said substituents are independently selected from one or more, preferably from 1-9 of the following groups: deuterium, fluoro or 1-2 of the following groups CC-cycloalkyl (2) optionally substituted C cycloalkyl, wherein said substituents are independently selected from one or more, preferably 1 to 4 from the following groups: deuterium, Ci-alkyl (preferably methyl), fluoro, cyano, aminocarbonyl (3) optionally substituted phenyl wherein said substituents are independently selected from one or more, preferably 1 to 2 of the following groups: deuterium, halo, cyano, C-S-alkyl, C-C alkylamino, di (C -C-alkyl) amino, C-C-alkylaminocarbonyl, di (Ci-alkyl) aminocarbonyl, Ci-alkoxy (4) optionally mono- or disubstituted amino wherein said substituents are independently selected from the following groups: deuterium, Ci-alkyl (which is unsubstituted or substituted by one or more substituents selected from the group of deuterium, fluoro, chloro, hydroxy ), phenylsulfonyl (which is unsubstituted or substituted by one or more, preferably one, C-C-alkyl, C-C-alkoxy, di (C alkyl) amino-C alkoxy) (5) substituted sulfonyl wherein said substituent is selected from the following groups: C-S-alkyl (which is unsubstituted or substituted by one or more substituents selected from the group of deuterium, fluoro), pyrrolidin (which is Nezam1. Способ лечения рака, выбранного из группы, состоящей из нейробластомы, саркомы Юинга или рабдомиосаркомы, включающий введение терапевтически эффективного количества соединения формулы (I)гдеА представляет гетероарил, выбранный из группы, состоящей из:R1 представляет один из следую
